(19)
(11) EP 2 903 616 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
07.02.2018 Bulletin 2018/06

(45) Mention of the grant of the patent:
13.12.2017 Bulletin 2017/50

(21) Application number: 13773731.8

(22) Date of filing: 04.10.2013
(51) International Patent Classification (IPC): 
A61K 31/496(2006.01)
A61P 35/00(2006.01)
 A61K 31/7068(2006.01)
(86) International application number:
PCT/EP2013/070741
(87) International publication number:
WO 2014/053650 (10.04.2014 Gazette 2014/15)

(54)

USE OF MASITINIB IN COMBINATION WITH GEMCITABINE FOR TREATING A SUBGROUP OF PATIENTS SUFFERING FROM PANCREATIC CANCER

VERWENDUNG VON MASITINIB IN KOMBINATION MIT GEMCITABIN ZUR BEHANDLUNG VON EINER UNTERGRUPPE DER PATIENTEN MIT BAUCHSPEICHELDRÜSENKREBS

UTILISATION DU MASITINIB EN COMBINAISON AVEC LA GEMCITABINE POUR TRAITER UN SOUS-GROUPE DE PATIENTS SOUFFRANT D'UN CANCER DU PANCRÉAS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 04.10.2012 EP 12306214

(43) Date of publication of application:
12.08.2015 Bulletin 2015/33

(73) Proprietor: AB Science
75008 Paris (FR)

(72) Inventors:
  • MOUSSY, Alain
    F-75006 Paris (FR)
  • KINET, Jean-Pierre
    Lexington, MA 02420 (US)
  • PIQUEMAL, David
    F-30380 Saint-Christol-les-Ales (FR)

(74) Representative: Icosa 
83 avenue Denfert-Rochereau
75014 Paris
75014 Paris (FR)


(56) References cited: : 
WO-A1-2008/115300
WO-A1-2012/170640
 WO-A1-2011/092338
WO-A2-2007/015935
   
  • GANG ZHOU ET AL: "Detection and Clinical Significance of CD44v6 and Integrin-Î1 in Pancreatic Cancer Patients using a Triplex Real-Time RT-PCR Assay", APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY ; PART A: ENZYME ENGINEERING AND BIOTECHNOLOGY, HUMANA PRESS INC, NEW YORK, vol. 167, no. 8, 14 June 2012 (2012-06-14) , pages 2257-2268, XP035098339, ISSN: 1559-0291, DOI: 10.1007/S12010-012-9752-2
  • HUMBERT MARTINE ET AL: "Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 5, no. 3, 1 January 2010 (2010-01-01) , pages e9430-1, XP009146696, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0009430
  • Business Wire: "AB Science reports phase 3 study results of masitinib in combination with Gemzar® for treatment of pancreatic cancer.", , 30 October 2012 (2012-10-30), XP002718427, Retrieved from the Internet: URL:http://www.businesswire.com/news/home/ 20121030006279/en/AB-Science-reports-phase -3-study-results#.Us5dA1O198E [retrieved on 2014-01-08]
  • G. DEPLANQUE ET AL: "A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer", ANNALS OF ONCOLOGY., vol. 26, no. 6, 9 April 2015 (2015-04-09), pages 1194-1200, XP055256745, NL ISSN: 0923-7534, DOI: 10.1093/annonc/mdv133
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).